| Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. | |
| | |
MedLine Citation:
|
PMID: 12814161 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Interleukin-17 (IL-17) is a novel cytokine secreted by activated human memory CD4+ T cells. In vivo IL-17 recruits neutrophils into the airways via the release of CXC chemokines (interleukin-8) from bronchial epithelial cells. Since neutrophils are implicated in pathogenesis of chronic obstructive pulmonary disease (COPD) chronic bronchitis (CB) and asthma, we hypothesized that there would be increased concentration of IL-17 in the airways of these patients. To test this hypothesis, we measured levels of IL-17 in induced sputum of COPD patients, chronic bronchitis and asthmatics and compared them with healthy controls. METHODS: Levels of IL-17 in induced sputum were measured via ELISA method in 19 COPD, 16 CB, 10 asthma and 11 control subjects. Airway responsiveness to methacholine was performed in people with FEV1 higher than 70% of predicted. RESULTS: There were no significant differences in IL-17 levels between control group and the other groups. However, levels of IL-17 in sputum of COPD patients were significantly lower than in asthma (P=0.004) and in CB (P=0.01) groups. Medians and (ranges) were as follows: asthma--37.6 pg/ml (18.8-55.7 pg/ml), CB 293 pg/ml (18.8-49.7 pg/ml) and COPD 24.6 pg/ml (0-34.1 pg/ml). Comparison of healthy control subjects (PC20 > 8 mg/ml) to a group with bronchial hyperreactivity, which consisted of asthmatics and CB patients, whose PC20 was less than 8 mg/ml, revealed that levels of IL-17 were significantly increased in the second group (P=0.02). Also, levels of IL-17 were significantly increased (P=0.02) in the asthmatic patients with bronchial hyperreactivity compared to healthy subjects. Moreover levels of IL-17 in sputum of all studied subjects correlated negatively with PC20 (r=-0.51, P=0.002). CONCLUSIONS: According to our results IL-17 is probably not involved in pathogenesis of stable COPD, but it may play a role in people with airway hyperresponsiveness. |
| | |
Authors:
|
A Barczyk; W Pierzchala; E Sozañska |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Respiratory medicine Volume: 97 ISSN: 0954-6111 ISO Abbreviation: Respir Med Publication Date: 2003 Jun |
Date Detail:
|
Created Date: 2003-06-19 Completed Date: 2003-07-15 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8908438 Medline TA: Respir Med Country: England |
Other Details:
|
Languages: eng Pagination: 726-33 Citation Subset: IM |
Affiliation:
|
Department of Pneumology, Silesian Medical Academy, Katowice, Poland. adagneic@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Asthma / metabolism, physiopathology Bronchitis, Chronic / metabolism, physiopathology Bronchoconstriction / drug effects* Bronchoconstrictor Agents / diagnostic use* Female Forced Expiratory Volume / physiology Humans Interleukin-17 / metabolism* Male Methacholine Chloride / diagnostic use* Middle Aged Pulmonary Disease, Chronic Obstructive / metabolism*, physiopathology Sputum / chemistry* Vital Capacity / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Bronchoconstrictor Agents; 0/Interleukin-17; 62-51-1/Methacholine Chloride |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Exhaled hydrogen peroxide correlates with the release of reactive oxygen species by blood phagocytes...
Next Document: Airway inflammation in asthma with incomplete reversibility of airflow obstruction.